Catalyst Calendar

Disc Medicine Presents Initial Results from RESTORE-PV Phase 2 Trial in Patients with Polycythemia Vera (PV) at the 14th Society of Hematologic Oncology (SOHO) Annual Meeting

Initial results from RESTORE-PV show DISC-3405 increased hepcidin and lowered serum iron, translating to controlled hematocrit, reduced phlebotomy, and improved symptoms in PV patients DISC-3405 is the first monoclonal antibody targeting TMPRSS6 that has demonstrated phlebotomy reduction in

Lexaria Announces Closing of Exercise of Warrants for Approximately $5.9 Million in Gross Proceeds

KELOWNA, BC / ACCESS Newswire / September 9, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, today closed its previously announced exercise of certain outstanding warrants to purchase an aggregate of 453,969 shares of the Company’s common stock originally issued by the Company on...

NANOBIOTIX to Participate in the H.C. Wainwright 28th Annual Global Investment Conference

PARIS and CAMBRIDGE, Mass., Sept. 09, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO - NASDAQ: NBTX - the “Company”), a late-stage clinical biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer and other major diseases, today

Puma Biotechnology to Present at H.C. Wainwright’s 28th Annual Global Investment Conference

LOS ANGELES --(BUSINESS WIRE)--Sep. 9, 2026-- Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder, will provide an overview of Puma at 3:30 p.m. ET on Monday, September 14, at the H.C.

Royalty Pharma to present at upcoming investor conferences

NEW YORK, NY, September 9, 2026 — Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in the following upcoming investor conferences during the month of September: Morgan Stanley 24th Annual Global Healthcare Conference on Monday, September 14, 2026 at 2:35 p.m....

Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

MacroGenics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference

ROCKVILLE, MD, Sept. 09, 2026 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, today announced that Eric Risser, President and CEO of MacroGenics, will present at the H.C.

Oruka Therapeutics to Attend the 2026 Morgan Stanley Global Healthcare Conference

MENLO PARK, Calif., Sept. 09, 2026 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a clinical-stage biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases including plaque psoriasis and hidradenitis

Genelux Announces Publication of a Deep and Durable Response in a Platinum-relapsed Small Cell Lung Cancer Patient Following Systemically Delivered Olvi-Vec-Primed Immunochemotherapy

-- A platinum-relapsed SCLC patient achieved 16.7 months progression-free survival following Olvi-Vec and platinum rechallenge, exceeding the PFS achieved following platinum-based first-line therapy -- -- This patient also achieved 84.6% reduction in target lesion size, as previously reported by

First Infant Data from Ascendis Trial of Once-Weekly TransCon CNP (Navepegritide) Presented at ESPE 2026

– Achondroplasia Foramen Magnum Score was stable or improved between baseline and Week 52 with TransCon CNP treatment – Treatment with TransCon CNP increased linear growth in the sentinel cohort, with an improvement in ACH-specific supine length Z-score of +0.42 from baseline through Week 52 –

AMGEN TO PRESENT AT THE MORGAN STANLEY 24TH ANNUAL GLOBAL HEALTHCARE CONFERENCE

THOUSAND OAKS, Calif., Sept. 9, 2026 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the Morgan Stanley 24 th Annual Global Healthcare Conference at 11:30 a.m. ET on Tuesday, September 15, 2026. Jay Bradner, executive vice president, Research and Development, Artificial Intelligence and Data

PureTech Founded Entity Seaport Therapeutics Reports Positive Topline Results from Phase 1 Driving Simulation Trial of GlyphAllo™ in Healthy Volunteers

RNS Number: 1273U PureTech Health PLC 09 September 2026 9 September 2026 PureTech Health plc PureTech Founded Entity Seaport Therapeutics Reports Positive Topline Results from Phase 1 Driving Simulation Trial of GlyphAllo™ in Healthy Volunteers PureTech Health plc (LSE: PRTC) (" PureTech "

Genmab A/S has published its Articles of Association

Genmab A/S has published its Articles of Association dated September 8, 2026. The Articles of Association can be found on Genmab’s website: https://ir.genmab.com/genmab-news Contact: Marisol Peron, Senior Vice President, Global Communications & Corporate

Silo Pharma to Highlight Patented Nose-to-Brain Drug Delivery Technology for PTSD at 2026 Nasal Innovation Forum

SARASOTA, FLA., Sept. 09, 2026 (GLOBE NEWSWIRE) -- Silo Pharma (Nasdaq: SILO) (“Silo” or “the Company”), ”), a developmental-stage biopharmaceutical company focused on novel therapeutics and drug delivery systems with a wholly owned managed AI agent platform, ...

AIM ImmunoTech Highlights Scientific Rationale, Supportive Data and Continued Advancement of Ampligen® in Pancreatic Cancer in New CEO Corner Video

Company continues to advance Phase 2 DURIPANC study and broader clinical strategy evaluating Ampligen’s potential to reshape the tumor microenvironment and enhance checkpoint inhibition Access it here OCALA, Fla., Sept. 09, 2026 (GLOBE NEWSWIRE) — AIM ImmunoTech Inc. (NYSE American:...

September 9, 2026

SOHO 2026Early Real-World Use and Hematologic Outcomes With Imetelstat in Patients With Myelodysplastic Syndromes: Insights From a United States Community Oncology Chart Review

September 9, 2026

SOHO 2026Correlation Between IL-8 and TNF-Alpha and Overall Survival in Imetelstat-Treated Patients With Myelofibrosis Relapsed or Refractory to a Janus-Associated Kinase Inhibitor in the IMbark Trial

September 9, 2026

SOHO 2026Updated Analysis of Overall Survival With Imetelstat in Relapsed or Refractory Myelofibrosis from IMbark Versus Real-World Data, and Assessment of Real-World Treatment Patterns: Updated Post Hoc Analysis With Extended Follow Up

Editas Medicine Reports Inducement Grants to New Chief Medical Officer

CAMBRIDGE, Mass., Sept. 09, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company developing transformative medicines for serious diseases, today announced the grant of an inducement award to the Company’s newly appointed Chief Medical Officer, Daniel Ory,

AEON Announces Positive Pilot Forced Degradation Results Supporting Analytical Comparability of ABP-450 to BOTOX®

ABP-450 and BOTOX ® demonstrated comparable rates of potency loss under thermal stress and similar site-specific oxidation patterns across methionine sites evaluated Results provide additional analytical evidence supporting comparability and establish the basis for AEON’s planned multi-lot

Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BRISBANE, Calif., Sept. 09, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies to transform the lives of patients, today announced the granting of inducement awards on September 2, 2026 to five new employees

NeOnc Technologies Holdings, Inc. Announces Pricing of $15 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules with New and Existing Institutional Investors

CALABASAS, Calif., Sept. 09, 2026 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (Nasdaq: NTHI) ("NeOnc" or the "Company"), a multi-Phase 2 clinical-stage biopharmaceutical company developing novel therapies for central nervous system (CNS) cancers, today announced that it has entered into

IN8bio Appoints Oxana Polyakova, Ph.D., as Senior Vice President of Research & Development

Renowned γδ T cell and T cell engager (TCE) expert brings two decades of drug discovery and development experience to IN8bio Appointment strengthens IN8bio’s leadership and domain expertise as they advance their novel γδ T cell engager platform NEW YORK, Sept.

MBX Biosciences to Participate in Upcoming Investor Conferences

CARMEL, Ind., and BURLINGTON, Mass., Sept. 09, 2026 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel precision peptide therapies for the treatment of endocrine and metabolic

ProQR Announces First Participant Dosed in Phase 1 Study of AX-0811 and Virtual Investor and Analyst Educational Event on September 30, 2026

LEIDEN, Netherlands & CAMBRIDGE, Mass., Sept. 09, 2026 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a clinical-stage company dedicated to changing lives through transformative RNA therapies based on its proprietary ADAR-mediated Axiomer™ RNA editing technology platform, today announced that the first participant has been dosed in the...

Humacyte Announces FDA Authorization Extending Symvess Shelf Life to 36 Months

– FDA authorizes extension of Symvess expiration dating from 18 months to 36 months – – Extended shelf life supported by additional stability data demonstrating Symvess continues to meet all established quality specifications throughout the 36-month dating period – DURHAM, N.C., Sept.

MetaVia Announces Preclinical Findings Supporting Biological Rationale for DA-1726's Waist Circumference Reduction

Tissue Distribution Study Shows Highest Exposure in Adipose Tissue and Prolonged Retention Consistent with Once-Weekly Dosing Findings Provide Mechanistic Support for the Differentiated Profile of DA-1726 CAMBRIDGE, Mass., Sept. 9, 2026 /PRNewswire/ -- MetaVia Inc.

Adagene Achieves Milestone in Collaboration with Exelixis for Advancement of SAFEbody® Antibody-Drug Conjugate Candidates

SAN DIEGO and SUZHOU, China, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a platform-driven, clinical-stage biotechnology company transforming the discovery and development of novel antibody-based therapies, today announced the achievement of a milestone in its

Palvella Therapeutics Appoints James R. Treat, M.D., Nationally Recognized Pediatric Dermatologist as Chief Medical Officer

Brings expertise in cutaneous vascular anomalies, including microcystic lymphatic malformations, venous malformations and angiokeratomas Leader in pediatric dermatology with nearly 20 years of distinguished clinical, research, and academic experience Longstanding Palvella clinical collaborator and

Context Therapeutics Announces First Patient Dosed in Phase 1 Trial of CT-202

CT-202 is a Nectin-4 x CD3 T cell engaging bispecific antibody Phase 1 trial is evaluating CT-202 as a monotherapy treatment in patients with urothelial, colorectal, and triple-negative breast cancers PHILADELPHIA, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Context Therapeutics Inc.

Helus Pharma to Participate at the H.C. Wainwright 28th Annual Global Investment Conference in New York

CEO Michael Halstead to participate in a fireside chat on Monday, September 14, 2026 at 9:00 a.m. EDT NEW YORK and TORONTO, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Helus Pharma (Nasdaq: HELP) (Cboe CA: HELP) (the “Company” or “Helus Pharma”), a clinical-stage pharmaceutical company committed to helping

Helus Pharma to Participate at the H.C. Wainwright 28th Annual Global Investment Conference in New York

CEO Michael Halstead to participate in a fireside chat on Monday, September 14, 2026 at 9:00 a.m. EDT NEW YORK and TORONTO, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Helus Pharma (Nasdaq: HELP) (Cboe CA: HELP) (the “Company” or “Helus Pharma”), a clinical-stage pharmaceutical company committed to helping

Pyxis Oncology Announces Positive Updated Data from Phase 1 Monotherapy Study of Micvotabart Pelidotin (MICVO) in Second-Line and Beyond Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (2L+ R/M HNSCC)

MICVO demonstrated rapid and deep responses, with a 36% confirmed objective response rate (cORR) and 94% disease control rate (DCR), with clinical activity observed across HPV status and prior-treatment subgroups Substantial survival outcomes include median progression-free survival (mPFS) of 6.2

Autolus Therapeutics Announces FDA RMAT Designation Granted to Obe-cel for the Treatment of Systemic Lupus Erythematosus and Lupus Nephritis

Enrollment in LUMINA, the pivotal Phase 2 study of obe-cel in refractory lupus nephritis, is ongoing LONDON and GAITHERSBURG, Md., Sept. 09, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering

Fractyl Health to Participate in Upcoming September Investor Conferences

BURLINGTON, Mass., Sept. 09, 2026 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the Company or Fractyl), a clinical stage metabolic therapeutics company focused on pioneering novel approaches to treat obesity and type 2 diabetes (T2D), today announced that Harith Rajagopalan, M.D.,

Tyra Biosciences Reports Initial Phase 2 SURF302 Results Supporting the First Potential Oral Innovation in LG IR NMIBC with Dabogratinib

TYRA's mission is to make dabogratinib the clear first-line treatment choice for patients with LG IR NMIBC Favorable safety and tolerability results support chronic dosing potential No clinically significant hyperphosphatemia, nail toxicity or ocular toxicity; low frequency of transaminase TEAEs

Rezolute Provides Update on FDA Review of its Phase 3 sunRIZE Study Results in Congenital Hyperinsulinism

Data from the Phase 3 sunRIZE study remains under review by FDA The OLE Phase of the study is ongoing, with a high participation rate and several indicators of improved glycemic control, incl...

Opus Genetics Announces Positive Low Dose Cohort 1 Data from Phase 1/2 Clinical Trial of OPGx-BEST1 and Successful FDA Type C Meeting with Potential Phase 3 Dosing in 2027

Kura Oncology Launches Caspian Therapeutics with $50 Million Financing to Advance Menin Inhibition as a Potential Disease-Modifying Approach for Diabetes

– $50 million financing led by BVF Partners with participation from the T1D Fund, Invus, Montanova, Eli Lilly and Company, Kura Oncology, members of the Kura leadership team, and multiple, successful biotech entrepreneurs – – Preclinical studies with KO-7246 demonstrate selective expansion of

Fate Therapeutics Announces Encore Clinical Data Presentation of FT819 Off-the-Shelf CAR T-Cell Product Candidate at the CCR – West 2026 Meeting

SAN DIEGO, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases,

Cocrystal Pharma Announces Last Subject Dosed in Phase 1b Human Challenge Study Evaluating CDI-988 for Norovirus Prevention and Treatment

No serious adverse events reported to date Preliminary efficacy results expected in late 2026 or early 2027 MIAMI, Fla. And BOTHELL, Wash., Sept. 09, 2026 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq:...

Telix to Present at the Morgan Stanley 24th Annual Global Healthcare Conference and H.C. Wainwright 28th Annual Global Investment Conference

MELBOURNE, Australia and INDIANAPOLIS, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) advises that Dr. Christian Behrenbruch, Managing Director and Group CEO and Kevin Richardson, CEO, Precision Medicine will present at the upcoming Morgan Stanley

MannKind and Rose Pharma Inc Enter Licensing and Collaboration Agreement to Develop an Inhaled Rapid-Acting, Short-Duration GLP-1 for Weight Management

Collaboration combines Rose Pharma investigational rapid-acting GLP-1 receptor agonist with MannKind’s Technosphere ® inhalation technology MannKind to receive an equity interest and potential royalties while providing pharmaceutical development and manufacturing support through completion of a

IDEAYA Biosciences and Servier Announce First Patient Dosed in OptimUM-11 Global Phase 3 Registrational Trial of Darovasertib and Crizotinib as Adjuvant Therapy for Subjects with Uveal Melanoma

Evommune Announces Top-line Results from EVO756 Phase 2b Trial in Moderate-to-Severe Atopic Dermatitis

Mechanistic Characterization of Azetukalner: KV7 Binding, Enhanced Channel Opening, and Rational Polytherapy Potential in Epilepsy

Congress: European Epilepsy Congress (September 6, 2026) Authors: Sankar R, et al.

Tyra Biosciences to Present at the Cantor Global Healthcare Conference

CARLSBAD, Calif., Sept. 8, 2026 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today announced participation

Protara Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment Conference

NEW YORK, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that management will present at the H.C.

Spruce Biosciences to Participate in the H.C. Wainwright 28th Annual Global Investment Conference

SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Sep. 8, 2026-- Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today announced that Javier

Pyxis Oncology to Host Webcast to Present Updated Data from Phase 1 Monotherapy Study of Micvotabart Pelidotin (MICVO) in Second-Line and Beyond Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (2L+ R/M HNSCC)

Event to be webcast live on September 9, 2026 at 7:30 a.m. ET BOSTON, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, today announced that it will host a live webcast on